J&J Expands PFA Reach, Targets Untreated Atrial Fibrillation in Peru
Event summary
- Johnson & Johnson has launched its VARIPULSE pulsed field ablation (PFA) technology in Peru, expanding its presence in Latin America.
- The technology is intended for treating drug-refractory paroxysmal atrial fibrillation, a condition affecting over 50 million people globally.
- Clinica Delgado, part of the AUNA group, will be a key institution implementing the new technology.
- VARIPULSE offers integrated mapping and ablation, reducing fluoroscopy exposure and improving procedural efficiency.
- Peru is the latest country in Latin America to adopt the PFA technology, following others already using it in international reference centers.
The big picture
Johnson & Johnson’s expansion into Peru with VARIPULSE underscores the growing demand for minimally invasive cardiac arrhythmia treatments, particularly in regions with high rates of untreated atrial fibrillation. This move positions J&J to capitalize on a significant unmet need and reinforces its strategy of targeting specialized procedures with advanced technology. The launch also highlights the increasing importance of Latin America as a growth market for medical device companies, driven by rising healthcare expenditure and an aging population.
What we're watching
- Adoption Rate
- The speed at which Clínica Delgado and other Peruvian institutions integrate VARIPULSE will indicate the technology’s acceptance and potential market penetration within the country.
- Competitive Landscape
- How competing ablation technologies and companies will respond to J&J’s expanded presence in the Latin American market, particularly regarding pricing and features, warrants observation.
- Regulatory Scrutiny
- Increased adoption of advanced medical technologies like PFA may draw greater regulatory scrutiny regarding long-term patient outcomes and cost-effectiveness in Peru and other Latin American markets.
Related topics